This Small Cap Cancer Company ‘Hijacks Tumors From Within,” HC Wainwright Says
HC Wainwright has initiated coverage on Genenta Science SpA (NASDAQ:GNTA) with a Buy rating and a price target of $25. “We like Genenta’s…
Regeneron’s Price Target Cut On Dim Prospects For Its Flagship Eye Product
SVB has cut the price target from $738 to $630 and downgraded from Outperform to Market Perform to reflect Regeneron Pharmaceutical Inc’s (NASDAQ:REGN)…
HOOKIPA Gets FDA Nod For Initial-Stage Prostate Cancer Study
The U.S. Food and Drug Administration (FDA) has accepted HOOKIPA Pharma’s (NASDAQ: HOOK) Investigational New Drug (IND) application for HB-300, a novel arenaviral immunotherapy for the treatment of metastatic castration-resistant prostate cancer.
FDA Accepts AstraZeneca’s Submission For Low Breast Cancer Candidate Under Priority Review
The United States Food and Drug Administration (FDA) has accepted to review the supplemental Biologics License Application (sBLA) of AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo’s lead asset ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable
Soligenix Partners With SERB Pharmaceuticals To Supply Ricin Antigen For Ricin Toxin Poisoning Treatment
Soligenix Inc (NASDAQ:SNGX) has signed a worldwide license to supply its ricin antigen to SERB Pharmaceuticals for novel therapeutic treatment against…
IceCure Announces Regulatory Filing Submission For Approval Of ProSense In Canada For Indications Including Ablation Of Benign And Malignant Breast Tumors
Canadian hospitals and health care providers have expressed strong interest in ProSense® as they seek minimally invasive treatments for breast and other tumors
CAESAREA, Israel, July 25, 2022 /PRNewswire/
HOOKIPA Pharma Announces FDA Accepts Co.’s Investigational New Drug Application For HB-300 For The Treatment Of Metastatic Castration-resistant Prostate Cancer
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early 2023
Drug Master File (DMF) accepted to support future FDA submissions
Veru Announces UK’s Medicines and Healthcare Products Regulatory Agency Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients
Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced
Matinas BioPharma Announces Positive Opinion By The European Medicines Agency On Orphan Drug Designation For MAT2203 For The Treatment Of Cryptococcosis
Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform
Europe’s CHMP Recommends Approving AstraZeneca’s Asthma, Neuromuscular Disorder Treatments
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca Plc’s (NASDAQ:AZN) Ultomiris (ravulizumab)…